^
Association details:
| Biomarker: | MYD88 mutation |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug Class: | BTK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2037 Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom’s Macroglobulinemia (KMM1803)Clinically Relevant Abstract
Published date:
11/02/2023
Excerpt:
This study was conducted to estimate the efficacy and safety of the combination of rituximab, bortezomib, lenalidomide and dexamethasone in patients with WM in South Korea....R-VRD regiment could be helpful for MYD88 mutation negative or CXCR4 mutation positive patients. BTK inhibitors show superior response and survival outcomes for patients with MYD88 mutation positive and CXCR4 mutation negative.
